This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • IOP measures after intraocular chemotherapy

IOP measures after intraocular chemotherapy
Reviewed by Fiona Rowe

1 April 2018 | Fiona Rowe (Prof) | EYE - Paediatrics, EYE - Strabismus

This study aimed to describe the relationship between intravitreal chemotherapy and IOP in children with retinoblastoma and identify risk factors for pronounced elevations. This was a retrospective study of ten cases (ten eyes) with 17 encounters overall. Mean age was 33.6±9.4months. Mean IOP immediately after first injection was 45.4±14.3mmHg with a mean increase from baseline of 36.9±13.7. This reduced to <29mmHg in a mean of 153.3±97.5 seconds in 89.5% of cases. Mean IOP immediately after the second injection was 44.5±11 with a mean increase of 18.2±10.5 and reducing to 31±5mmHg by 150 seconds. Other than pre-injection digital massage, no patient needed further treatment to lower IOP. This study confirms a transient but substantial increase in IOP following intravitreal injection. The results indicate that the second injection can likely be safely given approximately three to five minutes after the first injection. There is a risk of CRAO when IOP exceeds the arterial perfusion pressure. This was exceeded in four cases but reduced in approximately one minute or less. Further research is warranted to determine if these acute elevations are of clinical significance. 

Intraocular pressure changes following intravitreal Melphalon and Topotecan for the treatment of retinoblastoma with vitreous seeding.
Karl MD, Francis JH, Iyer SI, et al.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2017;54(3):185-96.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency